Molina Healthcare (MOH) Stock Forecast & Price Target

Molina Healthcare is well positioned by its pure-play government-sponsored model, with more than 85% of members tied to state Medicaid contracts and over 5 million lives across Medicaid, Medicare, and Marketplace. Its outlook is strengthened by a credible earnings-recovery bridge built on Medicaid rate normalization, industry-leading Medicaid efficiency, and structural Duals upside, where a move from 6% toward its 16% Medicaid share could add roughly $1B of incremental 2029 revenue even before further gains from Florida CMS and M&A. The company also has meaningful operating leverage, as each 100 bps of Medicaid MCR improvement is worth about $5.00/share, while management’s conservative assumptions on RFP wins and AI-driven margin improvement leave additional upside unmodeled.

Molina Healthcare is exposed to an outsized reliance on government-sponsored programs, with more than 85% of members in Medicaid and four states—California, New York, Texas, and Washington—driving over half of enrollment, so state funding, rate adequacy, and contract renewal risk can quickly pressure results. Its outlook is further clouded by execution risk after embedded earnings were cut from >$11 to $9.00/share at the May 2026 Investor Day, reflecting the Florida CMS recalibration and the fact that medical costs in Medicaid are about 20% higher than three years ago after 4.5%, 6.5%, and 7.5% trend years. Even with management’s bullish 2027–2029 framework, the company faces OBBBA-driven membership attrition, a 62% Marketplace decline in 2026, and potentially material Washington reprocurement risk, making near-term cash flow and margin recovery too dependent on uncertain regulatory and operational outcomes.